OUR FOCUS
Creating Value-Driven Opportunities
Our highly-experienced investment bankers draw on their deep knowledge of the healthcare industry and unique market dynamics to help business leaders evaluate strategic alternatives and successfully execute complex, transformative transactions.
Our capabilities encompass both buy-side and sell-side advisory, strategic partnerships, joint ventures, and divestitures, including corporate carve-outs. Since 2009, we have completed 200+ M&A transactions with an aggregate value of $60B.
Recent Transactions
Undisclosed
Financial Advisor
Global License Agreement with Biosion
November 2024
Undisclosed
Exclusive Financial Advisor
AlloVir Merger with Kalaris Therapeutics
November 2024
UNDISCLOSED
Exclusive Financial Advisor
Acquisition of Opus Genetics, Inc.
October 2024
UNDISCLOSED
Exclusive Financial Advisor
Acquisition of Global Rights to BRM-1420 from Bridge Medicines
October 2024